Floatz logo

Silevertinib

EGFR-TKI Resistant Mutation

Black Diamond Therapeutics, Inc.Small moleculePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the EGFR-TKI Resistant Mutation cohort.

Asset / SponsorPhaseRating
Osimertinib
Tianjin Medical University Cancer Institute and Hospital
Phase 3BB
AZD9291
Shandong Cancer Hospital and Institute
Phase 3B
DALPICICLIB ISETIONATE
Tianjin Medical University Cancer Institute and Hospital
Phase 2CCC
Nintedanib
China Medical University Hospital
Phase 1/2CC
Gefetinib
China Medical University Hospital
Phase 1/2CC

Same molecule, other indications

Silevertinib is also rated in:

GBMDormant
B
Indicative ·
60 / 100
View asset →
central nervous system disorderDormant
CCC
Indicative ·
53 / 100
View asset →
brain cancerDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →